Company Overview
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +121.26% |
| 6 Months: | +73.90% |
| 3 Months: | +38.12% |
| 1 Month: | -8.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)46.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GHRS GH Research PLC PHARMA | 27.79 | -28.07 | $1.91B | 0.00% | -21.68% | -18.79% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 12.75M | 14.69M | 16.54M | 16.70M | 18.75M |
| Operating Income | - | -12.75M | -14.69M | -16.54M | -16.70M | -18.75M |
| EBITDA | - | -10.73M | -9.20M | -13.92M | -14.04M | -18.87M |
| Interest Expense | - | 10.00K | 9.00K | 8.00K | 8.00K | 6.00K |
| Pretax Income | - | -10.81M | -9.29M | -14.02M | -14.14M | -18.97M |
| Tax Provision | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | - | -10.81M | -9.29M | -14.02M | -14.14M | -18.97M |
| Diluted EPS | - | -0.19 | -0.15 | -0.23 | - | -0.31 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 30.68M | 41.22M | 50.25M | 60.68M |
| Operating Income | -30.68M | -41.22M | -50.25M | -60.68M |
| EBITDA | -22.41M | -35.21M | -38.60M | -47.89M |
| Interest Expense | 0 | 63.00K | 48.00K | 35.00K |
| Pretax Income | -22.46M | -35.59M | -38.96M | -48.26M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -22.46M | -35.59M | -38.96M | -48.26M |
| Diluted EPS | -0.43 | -0.68 | -0.75 | -0.79 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 254.36M | 226.30M | 188.27M | 288.23M |
| Current Assets | - | 168.54M | 164.09M | 154.22M | 285.98M |
| Cash & Equivalents | - | 165.96M | 78.42M | 100.79M | 246.25M |
| Inventory | - | - | - | - | - |
| Receivables | - | 90.00K | 297.00K | 1.73M | 1.29M |
| Total Liabilities | - | 4.55M | 7.33M | 9.32M | 8.53M |
| Current Liabilities | - | 4.55M | 6.70M | 8.95M | 8.38M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 0 | 974.00K | 624.00K | 512.00K |
| Total Equity | - | 249.82M | 218.97M | 178.95M | 279.70M |
| Shares Outstanding | - | 52.02M | 52.03M | 52.03M | 62.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -26.20M | -33.34M | -42.28M | -43.55M |
| Investing Cash Flow | - | -84.69M | -54.10M | 65.14M | 46.17M |
| Financing Cash Flow | - | 0 | -204.00K | -304.00K | 139.65M |
| Capital Expenditure | - | -67.00K | -100.00K | -49.00K | -121.00K |
| Free Cash Flow | - | -26.27M | -33.44M | -42.33M | -43.67M |
| Net Change in Cash | - | -110.89M | -87.64M | 22.55M | 142.27M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | -9.0% | -16.3% | -21.8% | -17.3% |
| ROCE % | -12.3% | -18.8% | -28.0% | -21.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Lynx1 Capital Management Lp | 19.33% | 13.26M | $374.82M |
| 2 | BVF Inc. | 12.61% | 8.65M | $244.45M |
| 3 | RA Capital Management, L.P. | 11.13% | 7.64M | $215.82M |
| 4 | FMR, LLC | 8.71% | 5.98M | $168.91M |
| 5 | RTW Investments LP | 8.65% | 5.93M | $167.69M |
| 6 | Deep Track Capital, Lp | 4.86% | 3.33M | $94.20M |
| 7 | Avoro Capital Advisors LLC | 2.62% | 1.80M | $50.87M |
| 8 | Foresite Capital Management VI LLC | 1.37% | 940.49K | $26.58M |
| 9 | Jefferies Financial Group Inc. | 1.04% | 712.30K | $20.13M |
| 10 | Blackrock Inc. | 0.70% | 480.29K | $13.57M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GHRS
Is GH Research (GHRS) Trading At A Premium To Fair Value? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOYzNIa0twTVlQS0NDbjJGelQ5em42RWlVZE1zNFhuTXZycGJpR05mSlE5WUhuZUxhR3V5R2paN1RQdWxXSWtMWHRCNkVtcC1HNFV1VkhzcGhoMUxYVWFocHpZcU9hREJUaWVCa1dXMHZuNmVHNnpxa3FpNWw2dEpYcVJ5R1NTbmxPUlkxQU…
GHRS Stock Price and Chart — NASDAQ:GHRS - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBDbDBfUnZOT1BSeUFtN1dBWnIwd2JMRkFhanBqdUsyU3RsTkpqMXVYTmZXM3JSaW9BS19WY1hzNS0zbG8zbFpBUy1Zc29yX3Q3dTY3YzVRbEdMaXhm?oc=5" target="_blank">GHRS Stock Price and Chart — NASDAQ:GHRS</a…
GH Research (GHRS) Stock Looks Stretched On Its 111% YTD Run - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxOMHVEYmxvNEdDVjNheVhQQ210V1J2M3FmSG44ZlBqZHlSVldpTk92OGJYXzJTRXgzbEdDOHNwU25keEdvTzZUWk9zRnhLNFZsMDVBWUFmLXR2a1lEdG1yc0h5TlpiWTU0RG1pVHQ0SmJ3SFh2bl9SSS1wY0pGc1c5MzcxRGtXclRWckF0bX…
GHRS - GH Research PLC Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9DLWZOX0FEYk10NHZLQUFRMWVqNnNTYnpoQUxWeU5OQmE1VGg2d2Fkb3dDTDE5TmJHajd2LVVtcXVSQTEzUWc?oc=5" target="_blank">GHRS - GH Research PLC Stock Price and Quote</a> <font color=…
Why Is GHRS Stock Rising Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNRVltaGRwdzRibHh3Ull4M0dMcWRfNFBtUC1DVXZaYkgzaWo4bjlZM0dhNUpRUWNYMmhORm9NdjhEX2VzOGdZLUNsOERCeDVGd284S0p2UmxZS1J0WkxxN3VvVkZhcG1ZdXVoTm85MFp5V0prRkhJeGxuUlZuV3RmM0RuRU04MDR4TE5Id3…
GH Research PLC (GHRS) grants 102,202 share options to director Michael Forer - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQWEpoVUxpT25kb09GTmJveG1NQjRMeG5JSm9pb3NGalBMbG1YcUFTLUd4NUdueTJSenE1R3lKenBOOXhyR3hCR21EUE02Y3ZTc2o0WXBfRTRIVmtwYVRDM2pPeWpBVXppWjVLZk1oek1KMGpuaW1RM3FkT0EyZ25lYXI4NFlFTkE0dWdoWX…
GHRS — Frequently Asked Questions
What is the current share price of GH Research PLC (GHRS)?
As of 2026-09-19 21:16 PDT, GH Research PLC (GHRS) trades at $27.79 on NasdaqGM. Its 52-week range is $11.94 to $30.64.
What is the market capitalisation of GHRS?
GH Research PLC (GHRS) has a market capitalisation of $1.91B on NasdaqGM.
What is the P/E ratio of GHRS?
GHRS trades at a trailing price-to-earnings (P/E) ratio of -28.07. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.40.
What is the return on equity (ROE) of GHRS?
GHRS has a return on equity (ROE) of -18.79%. Its return on capital employed (ROCE) is -21.68%.
Is GHRS a good stock to buy?
This page provides a data-driven analysis of GH Research PLC (GHRS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.